-
$ICPT +2% today$WBA +2% today$UPS + 3% today$NBIX flathttps://twitter.com/firetrader05/status/1224824943918977024 … -
Intercept Pharmaceuticals Inc
$ICPT Receives Average Rating of “Buy” from Analysts http://americanbankingnews.com/?p=13281560#stocks -
-
had to sell all my
$ICPT except for the 1 share I have framed in my basement...now it will go back to $400 -
Covered Call Alert: NTERCEPT PHARMACEUTICALS
$ICPT returning up to 23.33% through 19-Jun-2020 http://ideas.quantcha.com/2020/02/04/covered-call-alert-ntercept-pharmaceuticals-icpt-returning-up-to-23-33-through-19-jun-2020/ …pic.twitter.com/aEjbCVuLWC
-
$ICPT - Monthly performance of the algo based option alerts posted for ICPT https://sleekoptions.com/pps.aspx?sym=ICPT … -
$ICPT - Last six months, 13 option alerts peaked above 100% after they were triggered by the algo https://sleekoptions.com/goodsetups.aspx?sym=ICPT …pic.twitter.com/SNEBZmRzdP
-
Peak profit for the last 6 expired option alerts for
$ICPT 105.56 % | -9.80 % | 204.35 % | 6.67 % | 200.45 % | 0.00 % | https://sleekoptions.com/goodsetups.aspx?sym=ICPT …pic.twitter.com/x45baAjJZP
-
Intercept Pharmaceuticals
$ICPT Earns “Buy” Rating from Wedbush http://dispatchtribunal.com/?p=3224100 -
$ICPT stock was down -1.54 %. Turned Positive 0.73 % | (Red to green move) See other red to green mo ves using https://www.sleekoptions.com/sleekscan.aspx?did=ICPT …pic.twitter.com/knmDwWflHt
-
-
Insider Selling: Intercept Pharmaceuticals Inc
$ICPT EVP Sells 723 Shares of Stock http://theenterpriseleader.com/?p=2599807 -
$HEPA (+31% AH) Hepion announced positive#NASH findings that CRV431 prevented experimentally induced liver fibrosis to a greater extent than obeticholic acid (FXR), elafibranor (PPARα/δ), resmetirom (THR-β), and Aramchol (SCD1).$ICPT$GNFT$MDGL$GLMDhttps://www.accesswire.com/574373/Hepions-NASH-Drug-Candidate-CRV431-Demonstrates-Superior-Antifibrotic-Efficacy-in-Expanded-Human-Liver-Study … -
Genfit
$GNFT -8% ce 23/01(volumes significatifs): je n'ai pas vu de News de concurrents ou d'update de brokers. Je remarque que les sociétés NASH en P3$MDGL et$ICPT font l'objet d'attaques en 2020. La seule qui échappait à cette vague baissière était$GNFT cc@Laurent_Grassinpic.twitter.com/fxOXop2sen
-
JEFF thoughts on
#BIOTECH M&A, outlook on macro/micro " still large interest in M&A " (6:27)$VRTX (10:15)$BIIB (15:25)$GILD (19:03)$AMGN (22:09)$AMRN (25:15)$KOD (27)$FGEN (29)$ICPT (30)$EPZM (31)$SAGE (32)$ITCI (33)$RUBY$XBI$IBB$NBI#JPM20 https://players.brightcove.net/pages/v1/index.html?accountId=4090876629001&playerId=M0SQPuFae&videoId=6124162652001&autoplay=true … -
This is a fascinating insight into the commercial view from
$ICPT in#NASH First, will biopsy be required? They think... No. Second, what will the price be? Non-committal, but "specialty pricing" so high#LiverTwitter - a brief thread on use of OCA and the $$ involved 1/n https://twitter.com/adamfeuerstein/status/1217217847782342656 …pic.twitter.com/INF667VtIx
Prikaži ovu nit -
On the cusp of FDA approval for its NASH drug,
$ICPT CEO talks payers, pruritis, and price https://www.statnews.com/2020/01/14/on-the-cusp-of-fda-approval-ash-drug-intercept-ceo-payers-pruritis-price/ …#JPM20
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
